Advertisement

Neuroscience and Behavioral Physiology

, Volume 50, Issue 1, pp 109–114 | Cite as

Age-Related Features of α-Synuclein Pathology in the Brain on Modeling the Preclinical Stage of Parkinson’s Disease in Rats

  • D. V. PlaksinaEmail author
  • I. V. Ekimova
Article
  • 1 Downloads

The pathomorphological signs of Parkinson’s disease (PD), an untreatable neurodegenerative condition, include the formation of pathological α-synuclein-positive inclusions in neurons. Studies using a model of the preclinical stage of PD in middle-aged and elderly rats based on increasing suppression of brain proteasome activity, along with analysis by light and confocal microscopy, addressed the presence and locations of pathological α-synuclein-positive inclusions in dopaminergic neurons in the compact part of the substantia nigra (SNc) and olfactory bulb. In the model of BP, α-synuclein aggregates were located in the cytoplasm of dopaminergic neurons in the olfactory bulb and the cytoplasm and nuclei of dopaminergic neurons in the SNc. A characteristic feature of α-synuclein pathology in aging rats was deposition of larger α-synuclein aggregates in the bodies of nerve cells in these locations as compared with middle-aged rats.

Keywords

Parkinson’s disease lactacystin α-synuclein aggregates substantia nigra olfactory bulb aging rats 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    I. N. Abdurasulova, I. V. Ekimova, A. V. Matsulevich, et al., “Impairments to nonassociative learning in rats in conditions of an experimental model of the preclinical stage of Parkinson’s disease,” Dokl. Akad. Nauk., 476, No. 3, 353–356 (2017).Google Scholar
  2. 2.
    I. V. Ekimova, V. V. Simonova, M. A. Guzeev, et al., “Changes in the characteristics of sleep in a model of the preclinical stage of Parkinson’s disease in rats created by weakening the activity of the ubiquitin- proteasome system of the brain,” Zh. Evolyuts. Biokhim. Fiziol., 52, No. 6, 413–422 (2016).Google Scholar
  3. 3.
    H. Bernheimer, W. Birkmayer, O. Hornykiewicz, et al., “Brain dopamine and the syndromes of Parkinson and Huntington. Clinical, morphological and neurochemical correlations,” J. Neurol. Sci, 20, No. 4, 415–455 (1973).CrossRefGoogle Scholar
  4. 4.
    M. Bisaglia, S. Mammi, and L. Bubacco, “Structural insights on physiological functions and pathological effects of α-synuclein,” FASEB J., 23, No. 2, 329–340 (2009).CrossRefGoogle Scholar
  5. 5.
    H. Braak, E. Ghebremedhin, U. Rаb, et al., “Stages in the development of Parkinson’s disease-related pathology,” Cell Tissue Res., 318, No. 1, 121–134 (2004).CrossRefGoogle Scholar
  6. 6.
    M. B. Fares, N. Ait-Bouziad, I. Dikiy, et al., “The novel Parkinson’s disease linked mutation G51D attenuates in vitro aggregation and membrane binding of α-synuclein, and enhances its secretion and nuclear localization in cells,” Hum. Mol. Genet., 23, No. 17, 4491– 4509 (2014).CrossRefGoogle Scholar
  7. 7.
    K. A. Fujita, M. Ostaszewski, Y. Matsuoka, et al., “Integrating pathways of Parkinson’s disease in a molecular interaction map,” Mol. Neurobiol., 49, No. 1, 88–102 (2014).CrossRefGoogle Scholar
  8. 8.
    B. I. Giasson, J. E. Duda, I. V. Murray, et al., “Oxidative damage linked to neurodegeneration by selective α-synuclein nitration in synucleinopathy lesions,” Science, 290, No. 5493, 985–989 (2000).CrossRefGoogle Scholar
  9. 9.
    J. V. Hindle, “Ageing, neurodegeneration and Parkinson’s disease,” Age Ageing, 39, No. 2, 156–161 (2010).CrossRefGoogle Scholar
  10. 10.
    K. S. P. McNaught, D. P. Perl, A. L. Brownell, and C. W. Olanow, “Systemic exposure to proteasome inhibitors causes a progressive model of Parkinson’s disease,” Ann. Neurol., 56, No. 1, 149–162 (2004).CrossRefGoogle Scholar
  11. 11.
    G. Paxinos and C. Watson, The Rat Brain in Stereotaxic Coordinates, Academic Press, SDG (1998).Google Scholar
  12. 12.
    D. V. Plaksina, M. V. Chernyshev, M. N. Karpenko, et al., “Experimental modeling of a preclinical Parkinson’s disease stage in rats by intranasal lactacystin administration,” Neurodeg. Dis., 17, Suppl. 1, 1655 (2017).Google Scholar
  13. 13.
    A. H. Schapira, “Recent developments in biomarkers in Parkinson disease,” Curr. Opin. Neurol., 26, No. 4, 395 (2013).CrossRefGoogle Scholar
  14. 14.
    Y. Tanaka, S. Engelender, S. Igarashi, et al., “Inducible expression of mutant α-synuclein decreases proteasome activity and increases sensitivity to mitochondria-dependent apoptosis,” Hum. Mol. Genet., 10, No. 9, 919–926 (2001).CrossRefGoogle Scholar
  15. 15.
    T. Uchihara and B. I. Giasson, “Propagation of alpha-synuclein pathology: hypotheses, discoveries, and yet unresolved questions from experimental and human brain studies,” Acta Neuropathol., 131, No. 1, 49–73 (2016).CrossRefGoogle Scholar
  16. 16.
    E. A. Waxman and B. I. Giasson, “A novel, high-effi ciency cellular model of fi brillar α-synuclein inclusions and the examination of mutations that inhibit amyloid formation,” J. Neurochem., 113, No. 2, 374–388 (2010). 17. J. L. Webb, B. Ravikumar, J. Atkins, et al., “α-Synuclein is degraded by both autophagy and the proteasome,” J. Biol. Chem., 278, No. 27, 25009–25013 (2003).CrossRefGoogle Scholar
  17. 17.
    S. Yu, X. Li, G. Liu, et al., “Extensive nuclear localization of α-synuclein in normal rat brain neurons revealed by a novel monoclonal antibody,” J. Neurosci., 145, No. 2, 539–555 (2007).CrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2019

Authors and Affiliations

  1. 1.Sechenov Institute of Evolutionary Physiology and BiochemistryRussian Academy of SciencesSt. PetersburgRussia

Personalised recommendations